What this is
- How it works
- How it works isn't classified yet
- Tested for
- Advanced Pancreatic Cancer
- Main trialPhase 3
- “This is a randomized, double-blind, multi-center, phase III study to evaluate the efficacy and safety, pharmacokinetic profile and immunogenicity of MRG004A in patients with advanced pancreatic cancer.”In the company’s words, NCT07138846 on ClinicalTrials.gov
Other drugs for Advanced Pancreatic Cancer
- CAM2029Camurus AB · Phase 3
- Immuncell-LCGC Cell Corporation · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- XNW28012Evopoint Biosciences Inc. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- DaraxonrasibRevolution Medicines · Phase 3
Coming up1
- Jun 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Jun 2027 | A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer | |
| Phase 1/2Completed | 20 Mar 2024 | A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026